Lai K, Conway R M, Crouch R, Jager M J, Madigan M C
Save Sight Institute & Discipline of Ophthalmology, University of Sydney, Sydney, NSW, Australia.
Exp Eye Res. 2008 Jun;86(6):936-41. doi: 10.1016/j.exer.2008.03.010. Epub 2008 Mar 16.
Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) are involved in tumour invasion, metastasis and angiogenesis, and have been implicated as progression markers in uveal melanoma, although their topographical expression has not been fully described. In this study we compared the distribution and specificity of several classes of MMPs (MMP-1, -2, -9, -19, and MT1-MMP) and physiological MMP inhibitors (TIMP-2 and -3) in different regions of the tumour microenvironment and adjacent choroid in a series of primary uveal melanomas. Paraffin sections of untreated uveal melanomas (n=18, 3/18 spindle; 11/18 mixed, and 4/18 epithelioid) were examined for MMP-1 (collagenase 1), MMP-2 and MMP-9 (gelatinases A and B), MT1-MMP (membrane-type 1-MMP), MMP-19, TIMP-2 and TIMP-3 (tissue inhibitors of MMPs), using indirect peroxidase immunohistochemistry. The distribution and intensity of immunolabelling was graded semi-quantitatively (0-3) by 2 independent observers. Non-parametric analyses were used to test for associations between tumour cell type, and the average grade of MMP or TIMP expression. Immunostaining for MMP-1, -9, -19 and MT1-MMP was > or =Grade 2 in more than 70% of specimens, and a heterogeneous pattern of MMP-1, -9, MT1-MMP and TIMP-3 expression was observed. At the tumour-scleral interface (TSI), melanoma cells had a flattened morphology and a much reduced MMP and TIMP expression, with a high expression in tumour areas adjacent to the TSI. Tumour vasculature and stromal cells strongly expressed MMP-2. We also observed heterogeneous immunostaining of the vasculature by MMP-1, -9, MT1-MMP and TIMP-2 antibodies, and of the extravascular matrix by MMP-9 antibody. The distinct immunostaining patterns observed for MMPs and TIMPs within uveal melanoma are consistent with their involvement in tumour growth and angiogenesis. In particular, the heterogeneous expression within regions of the tumours, and the localized expression in vasculature and stromal cells emphasises the importance of the tumour microenvironment in the pathogenesis of uveal melanoma (and other tumours).
基质金属蛋白酶(MMPs)和MMP组织抑制剂(TIMPs)参与肿瘤侵袭、转移和血管生成,在葡萄膜黑色素瘤中被认为是进展标志物,尽管它们的拓扑表达尚未得到充分描述。在本研究中,我们比较了一系列原发性葡萄膜黑色素瘤肿瘤微环境不同区域和相邻脉络膜中几类MMPs(MMP-1、-2、-9、-19和MT1-MMP)和生理性MMP抑制剂(TIMP-2和-3)的分布和特异性。对未经处理的葡萄膜黑色素瘤石蜡切片(n=18,18例中3例为梭形;11例为混合性,4例为上皮样)进行检测,采用间接过氧化物酶免疫组织化学法检测MMP-1(胶原酶1)、MMP-2和MMP-9(明胶酶A和B)、MT1-MMP(膜型1-MMP)、MMP-19、TIMP-2和TIMP-3(MMP组织抑制剂)。免疫标记的分布和强度由2名独立观察者进行半定量分级(0-3级)。采用非参数分析检测肿瘤细胞类型与MMP或TIMP表达平均分级之间的关联。在超过70%的标本中,MMP-1、-9、-19和MT1-MMP的免疫染色≥2级,并且观察到MMP-1、-9、MT1-MMP和TIMP-3表达的异质性模式。在肿瘤-巩膜界面(TSI),黑色素瘤细胞形态扁平,MMP和TIMP表达显著降低,而在TSI相邻的肿瘤区域表达较高。肿瘤血管和基质细胞强烈表达MMP-2。我们还观察到MMP-1、-9、MT1-MMP和TIMP-2抗体对血管的异质性免疫染色,以及MMP-9抗体对血管外基质的异质性免疫染色。在葡萄膜黑色素瘤中观察到的MMPs和TIMPs独特免疫染色模式与其参与肿瘤生长和血管生成一致。特别是,肿瘤区域内的异质性表达以及在血管和基质细胞中的局部表达强调了肿瘤微环境在葡萄膜黑色素瘤(和其他肿瘤)发病机制中的重要性。